您当前所在的位置:首页 > 产品中心 > 产品信息
Pemirolast_分子结构_CAS_100299-08-9)
点击图片或这里关闭

Pemirolast

产品号 DB00885 公司名称 DrugBank
CAS号 100299-08-9 公司网站 http://www.ualberta.ca/
分子式 C10H8N6O 电 话 (780) 492-3111
分子量 228.21012 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 763

产品价格信息

请登录

产品别名

标题
Pemirolast
IUPAC标准名
9-methyl-3-(2H-1,2,3,4-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
IUPAC传统名
pemirolast
商标名
Alamast
别名
Pemirolast Potassium
Pemiroplast Potassium
Pemirolastum [INN-Latin]

产品登记号

PubChem SID 46509034
PubChem CID 57697
CAS号 100299-08-9

产品性质

疏水性(logP) 0

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Pemirolast potassium is a slightly yellow powder that is soluble in water. It is a mast cell stabilizer that acts as an antiallergic agent. As an ophthalmic aqueous sterile solution, pemirolast is used for the prevention of itching of the eyes caused by allergies such as hay fever, and allergic conjunctivitis. Pemirolast is potentially useful for prophylaxis of pulmonary hypersensitivity reactions to drugs such as paclitaxel.
Indication For the prevention of itching of the eyes caused by allergies such as hay fever, and allergic conjunctivitis
Pharmacology Pemirolast is used for the prophylactic treatment of itching of the eye associated with allergic conjunctivitis. Pemirolast potassium is a mast cell stabilizer that inhibits the in vivo Type I immediate hypersensitivity reaction. Pemirolast inhibits the antigen-induced release of inflammatory mediators (e.g., histamine, leukotriene C4, D4, E4) from human mast cells. Allergic reactions lead to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis and vasodilatation (allowing blood fluids to enter the area to cause swelling). Pemirolast is a histamine H1 antagonist. It competes with histamine for the normal H1-receptor sites on effector cells of blood vessels to provide effective, temporary relief of watery and itchy eyes.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic (Ophthalmic)
Half Life 4.5 hours (Ophthalmic)
Elimination Following topical administration, about 10-15% of the dose was excreted unchanged in the urine.
References
Tinkelman DG, Berkowitz RB: A pilot study of pemirolast in patients with seasonal allergic rhinitis. Ann Allergy. 1991 Feb;66(2):162-5. [Pubmed]
External Links
RxList
Drugs.com

参考文献

  • Tinkelman DG, Berkowitz RB: A pilot study of pemirolast in patients with seasonal allergic rhinitis. Ann Allergy. 1991 Feb;66(2):162-5. Pubmed